Lynparza is the first PARP inhibitor to report 7-year follow-up data in newly diagnosed aOC2
| Study design | Efficacy | Safety profile | Indication
SOLO-1 demonstrated the efficacy of 1L Lynparza as maintenance therapy in newly diagnosed BRCAm aOC3
Primary PFS data cut-off: 17 May 2018.
*Analysis was performed after 198 progression events had occurred (in 50.6% of patients).
†’Not reached’ reflects persistent PFS in this treatment arm.
Patients receiving Lynparza presented a 67% reduction in risk of disease progression compared with placebo4
Follow-up PFS data cut-off: 5 March 2020. 5-year PFS follow-up data was a post hoc analysis and was not pre-specified and therefore not statistically significant.
*13 patients, all in the Lynparza arm, continued study treatment past 2 years.
More than 2/3 patients treated with Lynparza were alive at 7 years vs less than half of patients on placebo (significance not reached)2
7-year descriptive OS data cut-off: 7 March 2022. Median duration of follow-up approximately 88 months.
*Two-sided P value of <0.0001 required to declare statistical significance.
† ‘Not reached’ reflects persistent OS in this treatment arm.
Lynparza tablets were generally manageable, and the safety profile at 7 years remained consistent with the primary analysis1,2
7-year descriptive OS data cut-off: 7 March 2022. Median duration of follow-up approximately 88 months.
*Data are shown for treatment-emergent AEs that occurred in at least 10.0% of patients in either treatment group during study treatment or up to 30 days after discontinuation of study treatment.
†Includes patients with anaemia or decreased haemoglobin.
‡Includes patients with neutropenia, febrile neutropenia or decreased neutrophil count.
§Includes patients with thrombocytopenia or decreased platelet count.
Lynparza tablets therapeutic indications1
Lynparza tablets are indicated as monotherapy for:
- The maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.
- The maintenance treatment of adult patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.
Lynparza in combination with bevacizumab is indicated for:
- The maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.
Please consult the SmPC for further information before making any prescribing decisions.
1L, first-line; AE, adverse event; aOC, advanced Ovarian Cancer; BD, twice daily; BRCAm, BRCA1 or BRCA2 mutation; CI, confidence interval; FACT-O TOI, Functional Assessment of Cancer Therapy–Ovarian Trial Outcome Index; FIGO, Fédération Internationale de Gynécologie et d’Obstétrique; HR, hazard ratio; HRD, homologous recombination deficiency; HRQoL, health-related quality of life; ITT, intention to treat; OS, overall survival; PFS, progression-free survival; PR, partial response; RECIST, Response Evaluation Criteria in Solid Tumours; TFST, time from randomisation to first subsequent anti-cancer therapy/death; TSST, time to second subsequent therapy or death.
- Lynparza (olaparib) Summary of Product Characteristics.
- DiSIlvestro P, et al. J Clin Oncol. 2023;41:609–617.
- Moore K, et al. N Engl J Med. 2018;379:2495–2505.
- Banerjee S, et al. Lancet Oncol. 2021;22:1721–1731.
GB-73567 | Date of Preparation: July 2026
Privacy Policy Terms of Use Contact Us Information for General Public Accessibility
Cookie Preferences
© Merck Sharp & Dohme (UK) Limited 2026. All rights reserved.
© AstraZeneca 2026.
GB-73578 | Date of Preparation: July 2026
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Merck Sharp & Dohme (UK) Limited (Tel: 0208 154 8000).
